Drug intelligence / Profile preview

rFPV-HIV

Development stage: Phase 1
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics

Overview

rFPV-HIV is a recombinant fowlpox virus (FPV) vector-based vaccine developed for the prevention of HIV infection. It is designed to deliver specific HIV genes, such as env/gag sequences and modified tat/rev/nef-RT sequences, to HIV-uninfected adults. The vaccine aims to elicit an immune response, particularly cytotoxic T-cell responses, which are believed to be crucial in controlling HIV infection and disease. It has been evaluated for its safety and immunogenicity in clinical trials.

Targets

HIV-1 antigens

Beyond the preview

Go deeper on rFPV-HIV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rFPV-HIV.

Explore the full profile